Table 2.
Clinical trials with plant toxin-containing immunotoxins for cancer therapy #.
| Immunotoxin | Antigen Target | RIP | Diseases | Clinical Phase | Ref. |
|---|---|---|---|---|---|
| VB6-845 | EpCAM | deBouganin | Carcinoma | I | [40] |
| HuM-195/rGel | CD33 | r-Gelonin | Leukemia | I | [41] |
| B43-PAP | CD19 | PAP | ALL | I/II | [42] |
| H65-RTA | CD5 | RTA | CTCL | I | [43] |
| T101-RTA | CD5 | RTA | CLL | I | [44] |
| XOMAZYME-MEL | HMW mel. ag | RTA | Melanoma | I | [45,46] |
| Combotox | CD19/CD22 | dgRTA | ALL, NHL | I | [47,48] |
| 3A1-dgRTA | CD7 | dgRTA | T-LGL, ALL | II | [49] |
| IgG-HD37-dgA | CD19 | dgRTA | NHL | I | [50] |
| Xomazyme-791 | 72 kDa gp | dgRTA | Colon cancer | I | [51,52] |
| RFT-5-dgA | IL-2R (CD25) | dgRTA | CTCL, Melanoma | I/II | [53] |
| Anti-B4-bR | CD19 | bRicin | NHL, Multiple myeloma | I/II | [54,55] |
| N901-bR | CD56 | bRicin | SCLC | I | [56] |
| 260F9-rA | 55 kDa gp | RTA | Breast cancer | I | [57,58] |
| Ber-H2-SO6 | CD30 | Saporin-S6 | HD | I/II | [59,60] |
| F(ab’)2 BsAb | CD22 | Saporin-S6 | NHL | I | [61,62] |
| 4KB128 + HD6 | CD22 | Saporin-S6 | BCL | I | [63] |
# For more details about clinical trials, see the specific references. ALL: acute lymphoblastic leukemia; BCL: B-cell lymphoma; CD: cluster of differentiation; CLL: chronic lymphoblastic leukemia; CTCL: cutaneous T-cell lymphoma; dgRTA: deglycosylated ricin A chain; gp: glycoprotein; HD: Hodgkin’s disease; NHL: non-Hodgkin’s lymphoma; PAP: pokeweed antiviral protein; RTA: ricin A chain; RIP: ribosome-inactivating protein; SCLC: small cell lung carcinoma; T-LGL: T-cell large granular lymphocyte leukemia.